Ken Griffin Belite Bio, Inc Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Belite Bio, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 5,689 shares of BLTE stock, worth $366,371. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,689
Previous 5,211
9.17%
Holding current value
$366,371
Previous $328,000
14.63%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BLTE
# of Institutions
19Shares Held
270KCall Options Held
0Put Options Held
0-
Gamma Investing LLC Foster City, CA122KShares$7.89 Million0.01% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL83.6KShares$5.39 Million0.02% of portfolio
-
State Street Corp Boston, MA20.1KShares$1.29 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA12.8KShares$821,2930.0% of portfolio
-
Jpmorgan Chase & CO New York, NY8.16KShares$525,6320.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.6B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...